Novo Nordisk's Wall Street Ambitions Meet a Market That Wants Proof, Not Promises
Published on 09/24/2026 at 14:20 | Editorial boerse-global.de
Novo Nordisk is keeping its options open on the other side of the Atlantic. Chief executive Mike Doustdar told the Financial Times on Wednesday that the Danish drugmaker would consider a direct listing on the New York Stock Exchange, a move that could eventually replace its current American Depositary Receipts. For now, though, the company is not actively pursuing such a step, according to the manager.
The NYSE talk lands at an awkward moment for the share price. Novo Nordisk stock closed Wednesday at EUR 33.66, down 2.2%, and has now shed 24% since the start of the year. At EUR 33.40 in Thursday trading, the equity sits 39% below its 52-week high of EUR 54.86 — and not far above the 52-week low of EUR 30.25 that has become the line in the sand for chart watchers.
A Capital Markets Day That Raised More Questions Than Answers
Monday's capital markets day was meant to showcase the road ahead. Management pledged more than five potential multiblockbuster launches by 2030 and risk-adjusted pipeline revenue exceeding DKK 150 billion by 2035 — a figure that excludes any contribution from future acquisitions. Investors, however, were in no mood to celebrate. The stock dropped 8% immediately after the event, with analysts pressing hardest on future pricing power and the company's acquisition playbook.
The skepticism found its way into research notes the following day. Deutsche Bank trimmed its price target to DKK 245 from DKK 265 while keeping a sell rating. Jefferies, according to media reports, cut its own target to DKK 275 from DKK 285, maintaining a hold recommendation. The shared worry: Novo Nordisk risks ceding market power in its core diabetes and obesity franchise as Eli Lilly presses with rival offerings and the looming loss of patent protection on semaglutide threatens margins and pricing.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The Patent Clock Is Ticking
That single question dominates the debate — will mid-term revenue be enough to absorb the sales hole left behind once semaglutide's exclusivity lapses? Management's answer leans heavily on the next product generation, but the targets sit years away, and without firm confirmation that demand for existing GLP-1 treatments holds at record levels until the new wave arrives, market participants are increasingly pricing in transition risk.
The bull case rests on clinical data unveiled Monday. CagriSema, the company's lead obesity candidate, delivered an average weight loss of 12.4% in adults with type 2 diabetes, outpacing Eli Lilly's tirzepatide at 9.1% while matching it on HbA1c reduction. In a separate trial involving overweight or obese adults, CagriSema produced a 21.0% reduction in body weight against just 2.0% for placebo. Launch is penciled in for early 2027.
Beyond that, Novo Nordisk plans to roll out cagrilintide as a standalone therapy in 2028, alongside a higher-dose version of CagriSema, followed by the compound zenagamtid. The company also sees room to innovate on delivery methods.
Pills, Patients, and a Manufacturing Bet
Doustdar told Reuters on Tuesday that tablets could account for as much as half of the global obesity drug market by 2030, a shift that would move the needle decisively away from weekly injections. To capture it, Novo Nordisk aims to build manufacturing capacity for 15 million patients on oral therapies by the end of the decade, part of a broader ambition to treat more than 60 million people worldwide by 2030.
The balance sheet, according to management, is sturdy enough to fund bolt-on deals as well as larger acquisitions should the right opportunity appear.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
What to Watch
Technically, holding above the EUR 30.25 low would open the door to stabilization around current levels, with investors rewarding clinical progress on CagriSema and the long-range pipeline roadmap. A sustained break below that floor, by contrast, would risk deepening the correction as the market prices in a sharper hit to future earnings.
The next hard catalyst for reassessing growth prospects is likely to come from further advances on CagriSema's regulatory filings. Before that, Novo Nordisk will report results for the first nine months of the year on November 4 — a date that now carries more weight than usual. Shareholders must weigh whether pipeline wins outweigh the tangible transition risks stretching to the end of the decade.
Ad
Novo Nordisk Stock: New Analysis - 24 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
